Page 61 - 2020_09-Haematologica-web

Manifestations of disease in PKD
The effect of splenectomy. Arch Intern Med.
1966;118(1):75-78.
8. Mentzer WC Jr., Baehner RL, Schmidt-
Schonbein H, Robinson SH, Nathan DG. Selective reticulocyte destruction in erythro- cyte pyruvate kinase deficiency. J Clin Invest. 1971;50(3):688-699.
9. Nathan DG, Oski FA, Miller DR, Gardner FH. Life-span and organ sequestration of the red cells in pyruvate kinase deficiency. N Engl J Med. 1968;278(2):73-81.
10. Matsumoto N, Ishihara T, Nakashima K, Miwa S, Uchino F. Sequestration and destruction of reticulocyte in the spleen in pyruvate kinase deficiency hereditary non- spherocytic hemolytic anemia. Nihon Ketsueki Gakkai Zasshi. 1972;35(4):525-537.
11. Grace RF, Bianchi P, van Beers EJ, et al. Clinical spectrum of pyruvate kinase defi- ciency: data from the Pyruvate Kinase Deficiency Natural History Study. Blood. 2018;131(20):2183-2192.
12. Ferreira P, Morais L, Costa R, et al. Hydrops fetalis associated with erythrocyte pyruvate kinase deficiency. Eur J Pediatr. 2000;159 (7):481-482.
13. Hennekam RC, Beemer FA, Cats BP, Jansen G, Staal GE. Hydrops fetalis associated with red cell pyruvate kinase deficiency. Genet Couns. 1990;1(1):75-79.
14. van Beers E, Kuo K, Morton D, et al. Health related quality of life and fatigue in patients with pyruvate kinase deficiency. Blood. 2018;132(Suppl 1):4807.
15. van Beers EJ, van Straaten S, Morton DH, et al. Prevalence and management of iron over- load in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica. 2019;104(2): e51-e53.
16. van Straaten S, Bierings M, Bianchi P, et al. Worldwide study of hematopoietic allo- geneic stem cell transplantation in pyruvate kinase deficiency. Haematologica. 2018;103 (2):e82-e86.
17. Grace RF, Zanella A, Neufeld EJ, et al. Erythrocyte pyruvate kinase deficiency: 2015 status report. Am J Hematol. 2015;90(9):825-830.
18. Yang H, Merica E, Chen Y, et al. Phase 1 sin- gle- and multiple-ascending-dose random- ized studies of the safety, pharmacokinetics, and pharmacodynamics of AG-348, a first- in-class allosteric activator of pyruvate kinase R, in healthy volunteers. Clin Pharmacol Drug Dev. 2019;8(2):246-259.
19. Grace RF, Rose C, Layton DM, et al. Safety and efficacy of mitapivat in pyruvate kinase deficiency. N Engl J Med. 2019;381(10):933- 944.
20. Garcia-Gomez M, Calabria A, Garcia-Bravo M, et al. Safe and efficient gene therapy for pyruvate kinase deficiency. Mol Ther. 2016;24(7):1187-1198.
21. Thompson AA, Walters MC, Kwiatkowski J, et al. Gene therapy in patients with trans- fusion-dependent beta-thalassemia. N Engl J Med. 2018;378(16):1479-1493.
22. Yamaguti-Hayakawa GG, Ozelo MC. Gene therapy: paving new roads in the treatment of hemophilia. Semin Thromb Hemost. 2019;45(7):743-750.
23. Bianchi P, Fermo E, Glader B, et al. Addressing the diagnostic gaps in pyruvate kinase deficiency: consensus recommenda- tions on the diagnosis of pyruvate kinase deficiency. Am J Hematol. 2019;94(1):149- 161.
24. Hipkins R, Thompson J, Naidoo P, Bishay E, Djearaman M, Pratt G. Images in haematol-
ogy. Paravertebral extramedullary expression. Am J Hematol. 2014;89(4):380- haemopoiesis associated with pyruvate 384.
kinase deficiency. Br J Haematol. 2009;147 40. Iolascon A, Andolfo I, Barcellini W, et al. (3):275. Recommendations regarding splenectomy
25. Bachmeyer C, Khalil A, Kerrou K, Girot R, in hereditary hemolytic anemias. Gounant V. Idiopathic pulmonary arterial Haematologica. 2017;102(8):1304-1313. hypertension in a patient with pyruvate 41. Grace RF, Mark Layton D, Barcellini W. kinase deficiency and paravertebral How we manage patients with pyruvate extramedullary hematopoiesis. Ann kinase deficiency. Br J Haematol. Hematol. 2009;88(6):603-605. 2019;184(5):721-734.
26. Plensa E, Tapia G, Junca J, Perez R, Castella 42. Kristinsson SY, Gridley G, Hoover RN, E, Marti S. Paravertebral extramedullary Check D, Landgren O. Long-term risks after hematopoiesis due to pyruvate kinase defi- splenectomy among 8,149 cancer-free ciency. Haematologica. 2005;90(Suppl): American veterans: a cohort study with up ECR32. to 27 years follow-up. Haematologica.
27. Goh DH, Lee SH, Cho DC, Park SH, Hwang 2014;99(2):392-398.
JH, Sung JK. Chronic idiopathic myelofibro- 43. Rodeghiero F, Ruggeri M. Short- and long- sis presenting as cauda equina compression term risks of splenectomy for benign due to extramedullary hematopoiesis: a case haematological disorders: should we revisit report. J Korean Med Sci. 2007;22(6):1090- the indications? Br J Haematol. 1093. 2012;158(1):16-29.
28. Gouliamos A, Dardoufas C, Papailiou I, 44. Zanella A, Fermo E, Bianchi P, Valentini G. Kalovidouris A, Vlahos L, Papavasiliou C. Red cell pyruvate kinase deficiency: molecu- Low back pain due to extramedullary hemo- lar and clinical aspects. Br J Haematol. poiesis. Neuroradiology. 1991;33(3):284- 2005;130(1):11-25.
285. 45. Sandoval C, Stringel G, Weisberger J, 29. Sawhney H, Weedon J, Gillette P, Solomon Jayabose S. Failure of partial splenectomy to W, Braverman A. Predilection of hemolytic ameliorate the anemia of pyruvate kinase anemia-associated leg ulcers for the medial deficiency. J Pediatr Surg. 1997;32(4):641-642. malleolus. Vasa. 2002;31(3):191-193. 46. Kung C, Hixon J, Kosinski PA, et al. AG-348 30. Aessopos A, Kati M, Tsironi M, Polonifi E, enhances pyruvate kinase activity in red Farmakis D. Exchange blood transfusions blood cells from patients with pyruvate for the treatment of leg ulcerations in tha- kinase deficiency. Blood. 2017;130(11):1347-
lassemia intermedia. Haematologica. 2006; 1356.
91(5 Suppl):ECR11. 47. Grace RF, Cohen J, Egan S, et al. The burden 31. Alavi A, Kirsner RS. Hemoglobinopathies of disease in pyruvate kinase deficiency: and leg ulcers. Int J Low Extrem Wounds. patients' perception of the impact on health- 2015;14(3):213-216. related quality of life. Eur J Haematol.
32. Jansen G, Koenderman L, Rijksen G, Punt K, 2018;101(6):758-765.
Dekker AW, Staal GE. Age dependent 48. Oski FA. Clinical consequences of enzyme behaviour of red cell glycolytic enzymes in deficiencies in the erythrocyte. Ann Clin Lab haematological disorders. Br J Haematol. Sci. 1971;1(2):177-183.
1985;61 (1):51-59. 49. Lakomek M, Winkler H, Pekrun A, et al.
33. Warang P, Kedar P, Ghosh K, Colah R. Erythrocyte pyruvate kinase deficiency. The Molecular and clinical heterogeneity in influence of physiologically important pyruvate kinase deficiency in India. Blood metabolites on the function of normal and Cells Mol Dis. 2013;51(3):133-137. defective enzymes. Enzyme Protein.
34. Pissard S, Max-Audit I, Skopinski L, et al. 1994;48(3):149-163.
Pyruvate kinase deficiency in France: a 3- 50. Zanella A, Fermo E, Bianchi P, Chiarelli LR, year study reveals 27 new mutations. Br J Valentini G. Pyruvate kinase deficiency: the Haematol. 2006;133(6):683-689. genotype-phenotype association. Blood Rev.
35. Manu-Pereira Mdel M, Gonzalez-Roca E, 2007;21(4):217-231.
van Solinge WW, et al. Pyruvate kinase defi- 51. Diez A, Gilsanz F, Martinez J, Perez- ciency and severe congenital hemolytic ane- Benavente S, Meza NW, Bautista JM. Life- mia in a double heterozygous patient with threatening nonspherocytic hemolytic ane- paternal transmission of an early germ-line mia in a patient with a null mutation in the de novo mutation. Am J Hematol. 2015;90 PKLR gene and no compensatory PKM gene (12):E217-219. expression. Blood. 2005;106(5):1851-1856.
36. Grace RF, Bianchi P, van Beers EJ, et al. The 52. Aksu T, Yarali N, Fermo E, et al. A case with clinical spectrum of pyruvate kinase defi- pyruvate kinase deficiency remarkably sen- ciency: data from the Pyruvate Kinase sitive to heat. J Pediatr Hematol Oncol. Deficiency Natural History Study. Blood. 2018;40(7):e458-e460.
2018;131(20): 2183-2192. 53. Aydin Koker S, Oymak Y, Bianchi P, et al. A 37. Bagla S, Bhambhani K, Gadgeel M, Buck S, new variant of PKLR gene associated with Jin JP, Ravindranath Y. Compound heterozy- mild hemolysis may be responsible for the gosity in PKLR gene for a previously unrec- misdiagnosis in pyruvate kinase deficiency. J
ognized intronic polymorphism and a rare Pediatr Hematol Oncol. 2019;41(1):e1-e2. missense mutation as a novel cause of 54. Amankwah KS, Dick BW, Dodge S. severe pyruvate kinase deficiency. Hemolytic anemia and pyruvate kinase defi- Haematologica. 2019;104(9):e428-e431. ciency in pregnancy. Obstet Gynecol.
38. Lezon-Geyda K, Rose MJ, McNaull MA, et 1980;55(3 Suppl):42S-44S.
al. Pklr intron splicing-associated mutations 55. Wax JR, Pinette MG, Cartin A, Blackstone J. and alternate diagnoses are common in Pyruvate kinase deficiency complicating pyruvate kinase deficient patients with sin- pregnancy. Obstet Gynecol. 2007;109(2 gle or no Pklr coding mutations. Blood. Pt2):553-555.
2018;132(Suppl 1):3607. 56. Capron JP, Erlinger S. Barbituates and biliary
39. van Oirschot BA, Francois JJ, van Solinge function. Digestion. 1975;12(1):43-56.
WW, et al. Novel type of red blood cell pyru- 57. Grace RF, Glader B. Red blood cell enzyme vate kinase hyperactivity predicts a remote disorders. Pediatr Clin North Am. 2018;65 regulatory locus involved in PKLR gene (3):579-595.
haematologica | 2020; 105(9)
2239